Evidence map›Paper›PMID 27334845›Full record

ArticleScientific reports2016

7-dehydrocholesterol efficiently supports Ret signaling in a mouse model of Smith-Opitz-Lemli syndrome.

Myriam Gou-Fàbregas, Anna Macià, Carlos Anerillas, Marta Vaquero, Mariona Jové, Sanjay Jain, Joan Ribera, Mario Encinas

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Myriam Gou-FàbregasDepartment of Experimental Medicine, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida (IRB Lleida), Spain.
Anna MaciàDepartment of Experimental Medicine, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida (IRB Lleida), Spain.
Carlos AnerillasDepartment of Experimental Medicine, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida (IRB Lleida), Spain.
Marta VaqueroDepartment of Experimental Medicine, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida (IRB Lleida), Spain.
Mariona JovéMetabolomics Service, IRB Lleida, Rovira Roure, 80, Lleida 25198, Spain.
Sanjay JainDepartments of Internal Medicine (Renal Division) and Pathology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Joan RiberaDepartment of Experimental Medicine, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida (IRB Lleida), Spain.
Mario EncinasDepartment of Experimental Medicine, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida (IRB Lleida), Spain.
Universitat de Lleida · ESBiomedical Research Institute of Lleida · ESWashington University in St. Louis · US

Funding

NOVEL MECHANISMS REGULATING LOWER URINARY TRACT DEVELOPMENT AND INNERVATIONR01DK082531 · NIDDK · WASHINGTON UNIVERSITY · PI JAIN, SANJAY · 2009 to 2018
$3.3M
NIDDK NIH HHS R01 DK082531
6 · The paper itself

Abstract

Smith-Lemli-Opitz syndrome (SLOS) is a rare disorder of cholesterol synthesis. Affected individuals exhibit growth failure, intellectual disability and a broad spectrum of developmental malformations. Among them, renal agenesis or hypoplasia, decreased innervation of the gut, and ptosis are consistent with impaired Ret signaling. Ret is a receptor tyrosine kinase that achieves full activity when recruited to lipid rafts. Mice mutant for Ret are born with no kidneys and enteric neurons, and display sympathetic nervous system defects causing ptosis. Since cholesterol is a critical component of lipid rafts, here we tested the hypothesis of whether the cause of the above malformations found in SLOS is defective Ret signaling owing to improper lipid raft composition or function. No defects consistent with decreased Ret signaling were found in newborn Dhcr7(-/-) mice, or in Dhcr7(-/-) mice lacking one copy of Ret. Although kidneys from Dhcr7(-/-) mice showed a mild branching defect in vitro, GDNF was able to support survival and downstream signaling of sympathetic neurons. Consistently, GFRα1 correctly partitioned to lipid rafts in brain tissue. Finally, replacement experiments demonstrated that 7-DHC efficiently supports Ret signaling in vitro. Taken together, our findings do not support a role of Ret signaling in the pathogenesis of SLOS.

Indexed as

AnimalsBrainCells, CulturedCholesterolDehydrocholesterolsDisease Models, AnimalGlial Cell Line-Derived Neurotrophic FactorGlial Cell Line-Derived Neurotrophic Factor ReceptorsMembrane MicrodomainsMiceNeuronsOxidoreductases Acting on CH-CH Group DonorsProto-Oncogene Proteins c-retSignal TransductionSmith-Lemli-Opitz Syndrome7-dehydrocholesterol7-dehydrocholesterol reductaseCholesterolDehydrocholesterolsGlial Cell Line-Derived Neurotrophic FactorGlial Cell Line-Derived Neurotrophic Factor ReceptorsOxidoreductases Acting on CH-CH Group DonorsProto-Oncogene Proteins c-retRet protein, mouse

Identifiers

PMID27334845
PMCPMC4917867
OpenAlexW2468463672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.